George L. McLendon
George L. McLendon became the Howard R. Hughes Provost and Professor of Chemistry for Rice University in July, 2010. The Provost is the chief academic officer of the University.
The mission of the Provost’s Office is to promote and support excellence in all dimensions of the University's academic, research, scholarly and creative programs and activities. The Provost works with the University’s deans, as well as a team of Vice and Associate Provosts in fulfilling the academic leadership and administrative roles of the University and Provost’s Office. The Provost is a member of the University’s major planning and academic committees, including the Strategic Planning and Budget Priorities Committee, and serves ex officio as a member of the Faculty Senate. He continues to teach undergraduates, and conduct research in dry design for oncology
George L. McLendon was dean of the faculty of Arts and Sciences at Duke University, a position he assumed in July 2004. He was also professor of Chemistry and professor of Biochemistry and Experimental Cancer Therapeutics in the School of Medicine. In July 2008, he was also named dean of Trinity College, the undergraduate administrative unit of Arts and Sciences. Dr. McLendon was previously the R.W. Moore Professor and chair of the Department of Chemistry at Princeton University. A Texas native, he received his BS from the University of Texas at El Paso in 1972 and his Ph.D. from Texas A&M in 1976. He also taught at the University of Rochester, where he was the Tracy H. Harris Professor of Chemistry and professor of Biochemistry in the School of Medicine.
McLendon’s research is focused on inorganic and physical biochemistry. He has published over 200 peer reviewed papers and received national research awards, including the American Chemistry Society Pure Chemistry Award, the Eli Lilly Award in Ecochemistry, Sloan Dreyfus Award, and Guggenheim Fellowships. His publications range from solar nanotechnology to cell death pathways. His most recent research has direct implications for the diagnosis and treatment of cancer and other diseases. He has been involved in launching several biotech startups, including Tetralogic Pharmaceuticals.